See the Company Profile page, and the box on the right with "OTIC Ratios".
While I've only ever heard of a handful of companies that closed operations and distributed cash to shareholders, this situation does mean that OTIC is undervalued as it's closing price yesterday was $3.35.
On OTIPRIO for Acute otitis externa, $OTIC had a successful Phase 3 in Jan of 2017. PDUFA date for sNDA filing is March 2, 2018.
So, in Q1 2018 IF OTIPRIO is approved, $OTIC should see a nice bump.
In the meantime, I'd expect OTIC to file for Phase 3 on OTO-311 for Tinnitus AND either refile an application for Ménière's disease (based on data review- was failure due to poor trial design?) or to purchase IP from another company and pursue a new pipeline.
Know What You Own. My posts should not be construed as investment advice.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.